

GOVERNMENT OF KARNATAKA

No: HFW 313 ACS 2020

Karnataka Government Secretariat Vikasa Soudha Bengaluru, Date: 21.08.2020

CIRCULAR

Subject:

Guidelines for COVID-19 convalescent plasma therapy

Reference:

- 1. Updated clinical management protocol for COVID-19 from Ministry of Health Family Welfare, Government of India dated 03.07.2020
- 2. Guidance document on COVID-19 convalescent plasma (CCP) therapy from Indian Society of Transfusion Medicine (ISTM) dated 25.07.2020

Ministry of Health and Family Welfare, Government of India has allowed 'Off Label' use of convalescent plasma in patients with moderate COVID-19 disease who are not improving (oxygen requirement is progressively increasing) despite use of steroids. Special prerequisites while considering convalescent plasma therapy include:

- ABO compatibility and cross matching of the donor plasma
- Neutralizing titer of donor plasma should be above the specific threshold (if the latter is not available, plasma IgG titer (against S-protein RBD) above 1:640 should be used)
- Recipient should be closely monitored for several hours post transfusion for any transfusion related adverse events
- Use should be avoided in patients with IgA deficiency or immunoglobulin allergy
- Dose: Dose is variable ranging from 4 to 13 ml/kg (usually 200 ml single dose given slowly over not less than 2 hours

At present, use of convalescent plasma therapy is based on limited available evidence. As the situation evolves, and when more data become available, the evidence will be accordingly incorporated, and recommendation upgraded. Further, use of convalescent plasma therapy is subject to its limited availability in the state as of now. Currently, convalescent plasma therapy should only be used in a defined subgroup of patients as recommended.

This document provides guidelines for use of convalescent plasma therapy in COVID-19 patients. These guidelines will be updated as more evidence becomes available and based on GOI guidelines from time to time. However, an informed and shared decision making is essential before prescribing convalescent plasma therapy.

Jeef

COVID Convalescent Plasma (CCP) Donors

Searching for Donors:

- Blood bank should identify potential CCP donors from the list of COVID-19 recovered patients and recruit them as plasma donors.
- Blood bank should seek help and coordination of NGO (non-government organization) working for this "cause". Patient's family may be advised to search voluntary COVID-19 recovered patient willing for CCP donation through social media platforms and mass media amongst their 'near and dear ones' or/and through various NGOs which are maintaining a data-base of the persons who have recovered from COVID-19 disease.
- Family members may be advised to search for blood group compatible donors fulfilling donor eligibility criteria as vide below. Due care and caution has to be exercised by the blood bank to prevent paid/professional donations.
- Patients admitted in COVID institutions/ hospitals for treatment shall be counselled during their stay and also during discharge regarding uses of CCP and motivate them
- Since the donation is purely voluntary in nature, Government of Karnataka provides sum of Rs: 5000/- towards nutrition and care of donor (Annexure-1)
- ABO and Rh (D) blood group compatibility: Only ABO blood group compatibility is required in plasma donation. Rh (D) blood group can be ignored, provided anti-D antibodies are not present in Rh (D) Negative donor.

Compatibility of convalescent COVID plasma (CCP)

Patient Blood Group	Compatible CCP donor	
Α	A, AB	
В	B, AB	
AB	AB	
0	O, A, B, AB	

Additional requirements:

- Written informed consent for donation of convalescent plasma shall be taken. Refer donor Informed Consent Form (ICF), ICMR template (Annexure 2) from the donor in addition to regular donor health questionnaire cum consent form.
- Blood bank should possess license for plasmapheresis.
- Blood bank/hospital should have facility to measure serum protein.
- Blood bank should have facility to measure anti-SARS-CoV-2 IgG antibodies.

Eligibility criteria for the CCP donor

- To mitigate the risk of Transfusion Related Acute Lung injury (TRALI), donors shall be males or nulliparous females of over 50 kg of body weight.
- The donor shall be in the age group of 18 to 60 years.

1

- Recovered patient (CCP donor) should preferably have had symptoms (fever, cold, cough, etc.) since there is a greater probability of presence of anti-SARS-CoV-2 IgG antibodies as compared to an asymptomatic patient. However, even asymptomatic donors may be accepted, if anti-SARS-CoV-2 IgG antibodies are present.
- Complete resolution of symptoms at least 14 days prior to donation, preferably, with one negative RT-PCR test report for SARS-CoV-2 virus infection from nasopharyngeal/throat swab,

OR

Complete resolution of symptoms 28 days prior/ post discharge. RT-PCR negative report is not mandated in this situation.

- Prior diagnosis of COVID-19 disease is not mandatory since anti-SARS-CoV-2 lgG antibodies, being performed now, are direct evidence of prior COVID-19 disease.
- Donor should be advised to donate not more than twice a month. The maximum number of times that a donor can donate is twice a month/fortnightly (24 times a year).
 Note: In addition, donor eligibility criteria for whole blood/Apheresis donation will be followed in accordance to the Drugs & Cosmetics Act 1940 and rules therein (as amended till March 2020).

Blood Bank

Pre-donation health screening and testing:

- Once the donor has completed questionnaire on medical history, physical examination shall be done. If the donor is found eligible, the pre-donation samples collected (2 EDTA samples & 1 plain sample).
- Blood samples are tested for:
 - complete blood counts (CBC)
 - ABO and Rh D blood group
 - Antibody screen
 - Routine TTD (Transfusion Transmissible Diseases anti HIV 1 & 2, anti-HCV, HBsAg, test for Malaria and Syphilis)
 - Serum proteins and anti-SARS-CoV-2 IgG antibodies- these two tests are specifically for CCP plasmapheresis donation
- Total serum protein of > 6gm/dl is not (should not be) a criteria for CCP plasmapheresis, however presence of anti-SARS-CoV-2 lgG antibodies are pre-requisite for CCP plasmapheresis donation.
- Though the DCGI document dated 1st July 2020 mentions a titer of 1:640, it is recommended that in absence of quantitative test kits, at least the qualitative test (Yes/No) should be used for deciding upon donor eligibility. The donors with negative anti-SARS-CoV-2 IgG antibodies should be deferred.
- It is recommended to keep a donor serum sample frozen at < -30° Celsius

(jer)

Plasmapheresis procedure:

- Once the donor has been screened and found eligible, the plasmapheresis procedure shall be initiated
- Any automated cell separator (apheresis machine) may be used.
- Maximum CCP Volume collection that is allowed is 500 ml.
- If the apheresis machine does not have dedicated plasmapheresis program, the plateletpheresis procedure may be modified in a manner that at least 400 ml (two therapeutic doses of 200 ml each) plasma is obtained and minimum possible number (and volume) of platelets are collected. This by-product (where platelets are collected separately and later on suspended in the plasma) may be discarded or returned to the donor (depending on the cell separator). The maximum volume that can be collected in one session is 500 ml.

Storage of the CCP product:

- CCP has to be stored at temperature < -30° Celsius.
- Convalescent plasma collected through apheresis is aliquoted as 200ml bags and is frozen within 8 hours and stored as "Convalescent Frozen Plasma – For COVID patients only" at <-30 degree Celsius.
- The unit may be quarantined in "un-tested" if any test result is pending. It should be moved to "tested" compartment once the testing results are satisfactory.
- Separate shelf of deep freezer (or if possible, separate deep freezer) shall be dedicated for CCP.
- The plasma units should be transported in temperature-controlled conditions.

CCP Recipient

- As per ICMR definition: Patients admitted with RT-PCR confirmed COVID-19 illness and has either PaO2/ FiO2: 200-300 OR Respiratory Rate > 24/min and SaO2 < 93% on room air
- As per MOHFW definition: Adolescent or adult with presence of clinical features of dyspnea and or hypoxia, fever, cough, including SpO2 <94% (range 90-94%) on room air, Respiratory Rate ≥ 24 per minute OR Child with presence of clinical features of dyspnea and or hypoxia, fever, cough, including SpO2 <94% (range 90-94%) on room air, Respiratory Rate ≥ 24 per minute

Receiving of cross-match request and patient's sample:

- Once patient's request form for CCP is received, the blood group is performed, if not done
 previously. It is a good practice to perform group and screen for all patients at the time of
 admission.
- A separate consent form (besides regular consent that is part of hospital/blood bank protocol) is required. Refer patient Informed Consent Form (ICF) ICMR template; (Annexure 2).
- The request form should mention "off-label" use of CCP.

Jed .

- A blood component requisition by a qualified physician, from another designated COVID-19 treatment hospital or a hospital treating COVID-19 patient may also be accepted.
- The CCP of a particular blood group stored in a blood bank may be transferred or exchanged with another licensed blood center, depending on actual need as advised by physician. Appropriate documentation including blood component transfer records should be maintained by both the licensed blood centers.
 - Name and unique ID of patient
 - o Unique ID of the unit
 - ABO blood group of the patient and CCP Unit
 - o Date of issue (dd/mm/yyyy)
 - o Name and ID of the technical person who performed the crossmatch

Thawing and cross-matching the CCP unit:

- The plasma unit is thawed and the plasma bag segment is used for minor crossmatch with patient's RBC (red blood cells).
- ABO and Rh group specificity should be followed during allotment of convalescent plasma to the recipient.
- The crossmatch may be performed with the plasma bag segment. The bag should be thawed at 37° Celsius only if the crossmatch comes as compatible to prevent repeated thawing and refreezing of the unit.
- The minor crossmatch using donor plasma and patient red blood cells is performed
- If red cells alloantibody screening is performed on the donor's samples, no minor crossmatching is required. If the blood center does not have the red cells alloantibody screening facility, a minor crossmatch is indicated.
- If the unit is crossmatch compatible, the unit is issued with minimum labelling requirements as follows
- The minimal labelling requirement on the plasma bag:
 - Unique identification number
 - ABO blood group
 - o TTI screening negative results
 - o Name of the product: COVID-19 CONVALESCENT PLASMA
 - Date of Collection (dd/mm/yyyy)
 - Date of Expiry (dd/mm/yyyy)
 - Volume of the product (in ml)

Clinical use of CCP therapy

It is important to select the patient appropriately. Only moderately affected patients as defined below have shown to benefit from the CCP therapy. For infusion of plasma, standard operating procedure for transfusion of FFP should be followed with special care to monitor these patients during and post-24 hours of transfusion. Patient should be provided CCP therapy if:

(Jay)

- Moderate disease with increasing oxygen requirements should receive CCP therapy. It should be done before the patient goes into multiple organ failure. Failure of steroid therapy is not required before giving plasma.
- Patient should not have history of Ig A (immunoglobulin A) deficiency syndrome or allergy to immunoglobulins.
- One or two therapeutic units of 200-250 ml each should be administered to the patients on two consecutive days, 24 hours apart, if first unit is tolerated well, depending on the condition of the patient. It is advised that donor CCP units provided to patient should preferably be from two different donors.
- Patient should be closely monitored for adverse effects of plasma and appropriate intervention should be instituted, if needed.
- CCP therapy may be given along with other therapies like Remdesivir, Tocilizumab, etc.
- Patient should be monitored for improvement/deterioration after CCP therapy.
- Based on any new guidelines issued either by Government of India or Government of Karnataka

SOP for plasma transfusion (Annexure-3):

- Check the following details on the compatibility label attached to the bag; exactly match the details on the patient's chart
 - a. Patient's name
 - b. Patient's hospital reference number
 - c. Patient's ward
 - d. Patient's ABO & Rh group
- Check for any leakage from the plasma bag
- The thawed plasma collected should be taken directly to the ward without any delay
- FEP to be used immediately
- Once FEP is thawed, it cannot be cancelled
- Plasma once released from the Blood Bank shall not be taken back
- The final patient identity check:
 - a. The staff nurse should undertake final identity check at the Patient's bedside just before commencing the administration of the blood products
 - b. Check the bag for clot/hemolysis/contamination/precipitates
 - c. Check the patient's IP matches with the details on the compatibility label attached to the plasma bag
 - d. Check that the patient's blood group matches with that on plasma bag
 - e. Check the expiry date on the bag
- Always use a new sterile blood set
- Collect a pre-transfusion & post-transfusion blood and urine sample of the patient
- Rate of Infusion
 - Healthy individual 2 to 3 ml/Kg/hour (1 unit in 1.5hrs)
 - Volume overload/heart patients 1 ml/Kg/hr (1 unit in 4hrs)

()=1

Monitoring the transfused patient

- Monitor the patient:
 - a. Before starting the transfusion
 - b. As soon as the transfusion is started
 - c. 15 minutes after starting the transfusion
 - d. At least every hour during transfusion
 - e. On completion of the transfusion
 - f. 4 hours after completing the transfusion
 - At each of these stages, record the following information on the patient's chart.
 - a. Patient's general appearance
 - b. Temperature
 - c. Pulse
 - d. Blood pressure
 - e. Respiratory rate and oxygen saturation

• Record:

- a. Time of starting of transfusion
- b. Time of completion of transfusion
- c. Volume and type of all products transfused
- d. Blood unit number of all products transfused
- e. Any adverse effects: Severe reactions most commonly present during the first 15 minutes of a transfusion. All patients, in particular unconscious patients should be monitored during this period and for the first 15 minutes of each subsequent unit.

Donor Care

- The donor should be provided with good care before, during and after the plasmapheresis procedure
- Any adverse donor reactions should be adequately and promptly managed and recorded.
 (Annexure-4)
- The donor should be observed for 30 minutes and refreshment will be provided soon after the completion of procedure.
- Proper hydration will be ensured during the observation period. Juice and water will be provided
- He /she will be appreciated, thanked and a participation certificate will be provided before leaving the blood bank premises
- The donor is advised to take adequate fluid intake in next 24 hours.
- Since the donation is purely voluntary in nature, Government of Karnataka provides a sum of Rs: 5000/- towards nutrition and care of donor (Annexure-1)
- Potential donors with abnormal TTI test results should be referred to appropriate healthcare institutions for further investigation, confirmation, counseling, treatment and care.

Patient's sample storage

- The patient's sample has to be stored for seven days at -40° Celsius. Donor's sample may be archived at $< -30^{\circ}$ Celsius for future testing
- The existing infrastructure & facilities at district level shall be utilized for collection & infusion of CCP.
- The Blood safety officer at district level is identified nodal person. Deputy Director Blood Safety is the State Nodal Officer for overall monitoring of the activity.

(Jawaid Akhtar)

Additional Chief Secretary to Govt.

Health and Family Welfare Department

To:

- 1) Commissioner, BBMP
- 2) All Deputy Commissioners
- 3) All Chief Executive Officer of Zilla Panchayat
- 4) Commissioner, HFWS
- 5) Mission Director, NHM
- 6) Executive Director, SAST
- 7) Director, HFWS
- 8) Director, Medical Education.
- 9) All DHOs
- 10) All District Surgeons / District Surveillance Officer

Copy to:

- 1) Chief Secretary to Govt., of Karnataka
- 2) PS to Hon. Minister for HFW
- 3) PS to Hon. Minister for Medical Education.

Annexure - 1

Government of Karnataka order for provision of Rs: 5000/- towards nutrition and care of CCP donor



ಕರ್ನಾಟಕ ಸರ್ಕಾರದ ನಡವಳಿಗಳು

ವಿಷಯ: ಕೋವಿಡ್-19 ಸೋಂಕಿನಿಂದ ಗುಣಮುಖರಾದವರು ಕೋವಿಡ್-19 ಸಕ್ರಿಯ

ರೋಗಿಗಳ ಚಿಕಿತ್ಸೆಗಾಗಿ ಪ್ಲಾಸ್ಮಾ ದಾನ ಮಾಡಿದಲ್ಲಿ ಅವರಿಗೆ ಆರೈಕೆ ಭತ್ಯೆಯಾಗಿ

ರೂ.5,000/- ಗಳನ್ನು ನೀಡುವ ಬಗ್ಗೆ.

ಉಪ ಕುಲಪತಿ ಮತ್ತು ಅಧ್ಯಕ್ಷರು, ಕೋವಿಡ್-19ನ ಮಾನವ ಶಕ್ತಿ ಮತ್ತು ತರಬೇತಿ

ಕಾರ್ಯವಡೆ ಇವರ ಪತ್ರ ದಿನಾಂಕ:30.06.2020

ಪ್ರಸ್ಕಾಪನೆ

ಮೇಲೆ ಓದಲಾದ ಪತ್ರದಲ್ಲಿ, ದಿನಾಂಕ: 30.6.2020ರಂದು ಕೋವಿಡ್-19 ಗೆ ಸಂಬಂಧಿಸಿದ ಮಾನವ ಶಕ್ತಿ ಮತ್ತು ತರಬೇತಿ ಕಾರ್ಯಪಡೆಯ ತಜ್ಞರ ಸಮಿತಿಯ ಸಭೆ ನಡೆಸಿದ್ದು, ಸದರಿ ಸಭೆಯಲ್ಲಿ ಕೋವಿಡ್-19 ಸೋಂಕಿನಿಂದ ಚೀತರಿಸಿಕೊಂಡವರು ಆಸ್ಪತ್ರೆಯಿಂದ ಬಿಡುಗಡೆ ಹೊಂದಿದ 14ರಿಂದ 28 ದಿನಗಳೊಳಗಾಗಿ ಸಕ್ರಿಯ ಕೋವಿಡ್ ರೋಗಿಗಳ ಚಿಕಿತ್ಸೆಗಾಗಿ ಪ್ಲಾಸ್ಮಾ ದಾನ ಮಾಡಿದಲ್ಲಿ, ಅಂತಹವರಿಗೆ ಗುಣಮಟ್ಟದ ಆಹಾರ ವೆಚ್ಚವಾಗಿ ರೂ.5000.00 (ಐದು ಸಾವಿರ) ಗಳವರೆಗೂ ನೀಡಬಹುದೆಂದು ಶಿಫಾರಸ್ಸು ಮಾಡಿರುತ್ತಾರೆ.

ಪ್ರಸ್ತಾವನೆಯನ್ನು ಸರ್ಕಾರವು ಕೂಲಂಕಷವಾಗಿ ಪರಿಶೀಲಿಸಿ ಈ ಕೆಳಕಂಡಂತೆ ಆದೇಶಿಸಿದೆ ಸರ್ಕಾರದ ಆದೇಶ ಸಂಖ್ಯೆ:ಆಕುಕ 240 ಸಿಜಿಎಂ 2020 ಬೆಂಗಳೂರು,ದಿನಾಂಕ: 15.07.2020

ಪ್ರಸ್ತಾವನೆಯಲ್ಲಿ ವಿವರಿಸಿರುವ ಅಂಶಗಳ ಹಿನ್ನೆಲೆಯಲ್ಲಿ ಕೋವಿಡ್-19 ಸೋಕಿನಿಂದ ಗುಣಮುಖರಾದವರು ಆಸ್ಪತ್ರೆಯಿಂದ ಬಿಡುಗಡೆ ಹೊಂದಿದ 14ರಿಂದ 28 ದಿನಗಳೊಳಗಾಗಿ, ಸಕ್ರಿಯ ಕೋವಿಡ್ ರೋಗಿಗಳ ಚಿಕಿತ್ಸೆಗಾಗಿ ವ್ಲಾಸ್ಮಾ ದಾನ ಮಾಡಿದಲ್ಲಿ, ಅವರಿಗೆ ಆರೈಕೆ ಭತ್ಯೆಯಾಗಿ ರೂ.5000./- (ಐದು ಸಾವಿರ ರೂಪಾಯಿಗಳು ಮಾತ್ರ) ಗಳನ್ನು ನೀಡಲು ಕೆಳಕಂಡ ಪರತ್ರುಗಳಿಗೊಳಪಡಿಸಿ ಅನುಮೋದನೆ ನೀಡಿದೆ.

ಷರತ್ತುಗಳು:

- ಇದಕ್ಕೆ ತಗಲುವ ದೆಚ್ಚವನ್ನು 2020-21ನೇ ಸಾಲಿನಲ್ಲಿ ಸುವರ್ಣ ಅರೋಗ್ಯ ಸುರಕ್ಷಾ ಟ್ರಸ್ಟ್ ಲೆಕ್ಕ ಶೀರ್ಷಿಕೆ:2210- 80-101-0-01ರಡಿ ಒದಗಿಸಿರುವ ಅನುವಾನದಿಂದ ಭರಿಸತಕ್ಕದ್ದು
- 2. ಒಂದು ವ್ಯಕ್ತಿಯಿಂದ ಒಂದು ಬಾರಿಗೆ ಮಾತ್ರ ಪ್ಲಾಸ್ಥಾ ದಾನ ಪಡೆಯತಕ್ಕದ್ದು.
- ಅಂತಹ ವ್ಯಕ್ತಿಗಳ ಆಧಾರ್ ಸಂಖ್ಯೆ ,ವಿಳಾಸ ಮತ್ತು ದೂರವಾಣಿ ಸಂಖ್ಯೆಯನ್ನು ಕಡ್ಡಾಯವಾಗಿ ಪಡೆದು ದಾಖಲೆಗಳನ್ನು ನಿರ್ವಹಿಸತಕ್ಕದ್ದು.
- 4. ದಾನ ಪಡೆದ ಪ್ಲಾಸ್ಮಾಪನ್ನು ಯಾವ ವ್ಯಕ್ತಿಯ ಚಿಕಿತ್ಸೆಗೆ ಬಳಸಲಾಗುತ್ತದೆಯೋ ಆ ವ್ಯಕ್ತಿಯ ಸಂಪೂರ್ಣ ಮಾಹಿತಿಯ ದಾಖಲೆಯನ್ನು ನಿರ್ವಹಿಸತಕ್ಕದ್ದು.

..2

-2-

ಈ ಆದೇಶವನ್ನು ಆರ್ಥಿಕ ಇಲಾಖೆಯ ಟಿಪ್ಪಣಿ ಸಂಖ್ಯೆ;ಆಾ 249 ವೆಚ್ಚ-5/2020,ದಿನಾಂಕ:14,07,2020ರಲ್ಲಿ ನೀಡಿರುವ ಸಹಮಠದನ್ವಯ ಹೊರಡಿಸಲಾಗಿದೆ.

ಕರ್ನಾಟಕ ರಾಜ್ಯವಾಲು ಆದೇಶಾನುಸಾರ ಮತ್ತು ಅವರ ಹೆಸರಿನಲ್ಲಿ

ಸರ್ಕಾರದ ಅಧೀನ ಕಾರ್ಯದರ್ಶಿ ಆರೋಗ್ಯ ಮತ್ತು ಕುಟುಂಬ ಕಲ್ಯಾಣ ಇಲಾಖೆ

06 d d nert 182

11

Annexure - 2

Informed consent for COVID-19 convalescent plasma donation

- 1. General information about COVID-19 and convalescent whole blood or Plasma for COVID-19 treatment
- Coronaviruses are a large family of viruses which may cause illness in animals or humans. In humans, several coronaviruses are known to cause respiratory infections ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The most recently discovered coronavirus causes coronavirus disease COVID-19. COVID-19 is the infectious disease caused by the most recently discovered coronavirus. This new virus and disease were unknown before the outbreak began in Wuhan, China, in December 2019. COVID-19 is now a pandemic affecting many countries globally.
- The most common symptoms of COVID-19 are fever, dry cough, and tiredness. Other symptoms that are less common and may affect some patients include aches and pains, nasal congestion, headache, conjunctivitis, sore throat, diarrhea, loss of taste or smell or a rash on skin or discoloration of fingers or toes. These symptoms are usually mild and begin gradually. Some people become infected but only have very mild symptoms. Most people (about 80%) recover from the disease without needing hospital treatment. Around 1 out of every 5 people who gets COVID- 19 becomes seriously ill and develops difficulty breathing. Older people, and those with underlying medical problems like high blood pressure, heart and lung problems, diabetes, or cancer, are at higher risk of developing serious illness. However, anyone can catch COVID-19 and become seriously ill. People of all ages who experience fever and/or cough associated with difficulty breathing/shortness of breath, chest pain/pressure, or loss of speech or movement should seek medical attention immediately. If possible, it is recommended to call the health care provider or facility first, so the patient can be directed to the right clinic.
- The disease is believed to be spread primarily from person to person through small droplets from the nose or mouth, which are expelled when a person with COVID-19 coughs, sneezes, or speaks. These droplets are relatively heavy, do not travel far and quickly sink to the ground. People can catch COVID-19 if they breathe in these droplets from a person infected with the virus. This is why it is important to stay at least 1 meter) away from others. These droplets can land on objects and surfaces around the person such as tables, doorknobs and handrails. People can become infected by touching these objects or surfaces, then touching their eyes, nose or mouth. This is why it is important to wash your hands regularly with soap and water or clean with alcohol-based hand rub.



2. What will happen if you agree to donate blood?

Testing your blood

If you agree to donate plasma for the treatment of COVID-19, we will ask you to come to the blood donation centre and we will first take a small amount of your blood (about 10 mL), about a tablespoonful, from a vein in your arm using a single use sterile syringe and needle and do some tests that will tell us the type of blood that you have and also whether your blood can be used for treatment of COVID-19. If the amount of hemoglobin is too low or if your blood has the possibility of causing disease in another person, or you are not able to donate due to some other reason, we will not be able to accept your blood donation. If that happens, we will explain to you in detail the reasons why your blood cannot be taken, and if you need to have any medical treatment. If, however, you are suitable to donate, we will arrange a suitable time for the donation

Collection and storage of blood or plasma units

For the donation, we will ask you to come to the blood bank, where you will be given something to drink (water or juice) before the donation of blood or the liquid part of your blood (plasma). Donating blood is very simple. The nurse/doctor will then ask you to lie on a couch. The inner area of one of your elbows will be cleaned with an antiseptic solution before a trained health worker inserts a sterile needle, connected to a special apheresis machine, into your vein. A small tube will be connected to a machine that will collect the liquid part of the blood into a separate bag, and return the red part of your blood back to your body. To stop the blood from clotting, a liquid, known as an anticoagulant, will be automatically mixed with the blood as it is pumped from the body into the machine. The trained health worker will collect about half a litre (e.g. small mineral water bottle) of plasma. This procedure will take about 45-60 minutes. You will be given light refreshments after the procedure. After resting for about 15-30 minutes, you will be able to return to your normal activities, although you should avoid strenuous activities for the rest of the day. You should drink plenty of fluids over the next 24 hours. Your body will replace the lost fluid within about 36 hours.

What happens next?

The plasma has been collected will be stored in a freezer with an identification number. It will not have your name on it. When there is a patient who is likely to benefit from the use of plasma donated by you, it will be taken out from the stock, and brought to room temperature, and then given to the patient through a vein. We will keep a close watch on the patient and record everything, so that we learn from the experience and know more about its use in the treatment of COVID-19.

3. Possible risks and discomforts

Taking blood from your arm may sometimes cause bruising, mild pain or discomfort and in very rare circumstances, infection. We will take all preventive measures to minimize these risks. Some people may feel light-headed or little giddy, especially while donating plasma. This lasts for only a few minutes and quickly subsides.

1-9

4. Confidentiality

Any information that you provide and all test results will be treated confidentially. The blood bank personals that test your blood have the responsibility to inform you of all the blood test results, and to advise you on any treatment they think you will require.

5. Will I know who receives my blood?

A patient with early COVID-19 disease would receive your plasma. It is difficult to predict who exactly will receive the plasma that you donate. The person must have a compatible blood type to yours. Your name will not be on the plasma you have donated, it will just be identified with a unique donation number. So, no one will know whose plasma is being given to the patient. And you will not know who receives it either. But be assured that it will be used for a patient who requires it and all information about you and your donation will remain confidential.

6. Will the person who receives the plasma know who has provided it?

No. no-one, including the person who receives your plasma, will know who has provided the blood. This is so that your privacy can be protected. Be assured that the plasma that we collect will be treated with respect.

7. Expenses and payments

There will be no charges to you for any cost related to this donation. There will be no payment for you to participate in this donation either.

8. Participation and withdrawal from donation

You are free to decide whether or not to donate plasma. If you do not meet the donor suitability criteria, you will be immediately informed by the Blood Bank Medical Officer. Once your plasma has been collected, you can request that it is withdrawn at any time prior to it being transfused to a patient by informing the attending doctor. You cannot request that your plasma donation should not be used for transfusion, once it has been given to a patient. Your decision to request the discard of your plasma, if it has not been transfused, will not affect your future care.

9. 9. Who to contact if you have any questions?

If you have any questions, feel free to contact us at our Blood Bank Landline No.08026700001 your signature documents your permission for the donations.

Signature of Donor	Full Name	Date of Signature
		///



Annexure – 3 STANDARD OPERATING PROCEDURE

S5L CONCURRENT PLASMA COLLECTION ON S5L - COM - TEC

Purpose of this document: The purpose of these documents is to serve as a guide for experienced Apheresis personal with directions to utilize single needle Apheresis protocol on COM.TEC for acconcurrent Plasma Collection using Single Needle functionally closed S5L kit.

Scope/ Application: To collect the Concurrent Plasma using the platelet Apheresis protocol in the blood center with the help of the COM.TEC cell Separator for use in patients with actively bleeding and multiple coagulation deficiencies.

Responsibility: The procedure is performed by trained technical / medical personnel under the supervision of the Medical officer who is responsible for the smooth conduction of the process.

Principle: Concurrent:Plasma:collection during Platelet Apheresis is the procedure in which donor ablood is passed through:Centrifugal Apheresis machine which collects and desired Plasma and platelets from the blood and returns remaining blood components back to the donor body.

Prerequisites:

Materials Required:-

☐ COM.TEC Operator's Manual

- 1. Properly screened healthy donor is selected for donation. Donor selection follows the standard blood donation criteria.
- 2. The donor is tested for the Transfusion Transmitted Diseases prior to the procedure.
- 3. He should not be fasting prior to the procedure, however, should refrain from oily /fatty food.
- 4. A prominent and easily accessible antecubital vein on one of the arms is selected for Apheresis.
- 5. Informed written consent is taken from the donor.

COM.TEC Blood cell separator.
S5L Single needle Disposable kit
ACD-A anticoagulation -500 ml
Normal Saline (0.9% NACL) -1000ml
Material for Phlebotomy: Betadine, Spirit, Cotton Swabs, Sticking plaster, local anaesthetic
Tube Sealer
EDTA tubes for product sampling
Oral Calcium Tablets
Emergency Medicines Tray

Jed _

Procedure Description of the Concurrent Plasma with S5L Kit -

The procedure comprises five main steps. The Steps are as follows.

- Installation of the kit
- Priming
- Separation
- Reinfusion
- Removal of the Apheresis Kit

Operational Aspect:-

1. Selection of the Platelet Program

Press the 1 Key, instrument will display the software version installed along with the continue key option, press the continue key. Use up ''and Dawn''arrow keys for selecting the program Platelet Donation . Press ok key. Use the arrow keys to select Plt-5d and press Ok key.

NOTE: Printer should be always kept on during the procedure

2.	Ins	talla	ation of the Kit:-
	The	e M	essage install S5L prompts the operator to install the apheresis set.
			Open all pump leads
			Press the TURN PUMP key
			Deposit the packaging on the centrifuge door. Ensure that each pump line segment
			is located under the matching colour coded pump
			Take the rolled-up tubing out of the packaging, close the red inlet clamp just below
			the branch to the pre-sampling bag.
			Close the white needle clamp and suspend the connecting line literally at the upper
			right of the device
			Suspend the concentrate bag from the rear hook on the left of the device.
			Close the clamps between the concentrate bags and the PC sampling bag.
			Suspend the empty Bag above the return drip chamber
			Suspend the Plasma bag above clamp 4.
			Suspend the single needle bag at the left side of the plasma bag.
			Install all pump line segments so that colour of pump coding match.
			Press TURN PUMP keys.
			Close all Pump doors
			Install the return air drip chamber in the air detector.
			Install the plasma line in clamp 4 between the Y piece and drip chamber.
			Install the plasma line section marked by yellow tas into the Hb /Hct detector.
			Insert the line leading to empty bag in clamp 5
			Insert the return line clamp 1.
			Insert the inlet line of the cell pump into cell detector.
			Insert the green coloured drip chamber of the ADC line into the drip chamber and
			pull the drip chamber completely down.
			Install the ACD pump tubing into ACD pump and hit the TURN PUMPS key
			Install the caline line in alama ?



n ave siegië nevion co Liti. Leocophae voto itio	□ Install the single needle collecting /return line in clamp 3 between the blue marks. □ Install the inlet line leading to the single needle control with the red mark below the Y connector in clamp 6 □ Install the pressure filters into appropriate ports inlet-red, Outlet —Blue □ Install the separation chamber in the correct S5L Dual chamber holder.
detavite to misvane;	 □ Push the centrifuge holder onto the guide rail until it is felt to be locked. □ Pass the centrifuge tubing through the line guide. □ Rotate the chamber counter clockwise to verify the correct installation.
ver i rarediti ere aire	Close the centrifugation followed by placing the air protect in the holder.
3. Prir	
evidine alarm tenticon neitramana e entre chiana e entre chiana chiana e entre cito neitra e esto neitra e e esto neitra e e esto neitra e e esto neitra e e	nnect saline line to normal saline container. Connect the ACD tubing to ACD-A bag. After necting the lines, press PRIME key. The alarm test screen will be displayed following ssing the PRIME key. This test is performed automatically start and end of the test is icated by audible alarms. Alarm test is followed by priming of the whole kit using saline remove any air in the kit and processed saline is diverted to the diversion bag. Once ming is over machine gives an option for selecting second priming to remove all air still esent in the kit second priming is optional.
	TE:- Primed kit should be used within 8 hours and Installed kit should be used within hours
2.4	
	ncurrent Plasma Collection (Optional)
To	collect the concurrent plasma along with platelets-
	☐ Access the Procedure Menu screen by pressing Menu and OK key.
	Decreases the default platelet yield and PC volume to minimum value (1.0x1011 & 100mL).
	☐ Select the PLS Harvest option by using down ' 'and OK key.
	Enter the plasma volume by using plus (+) and minus (-) soft keys up to maximum 500 mL and press OK to confirm the changes.
5. Se	paration:
	Insert the needle after vein puncture. Open the white needle clamp and collect at least 20 ml of blood, close the white needle clamp and seal off the pre-sampling
	bag
	Open the red clamp on the inlet line
	☐ Apply the single needle cuff to the fully extended and relaxed upper arm of the donor
	☐ Connect the cuff to the cuff port to on the rear connector panel and ensure the
	connected line is not squeezed of kinked
	□ By pressing the START key the cuff is inflated up to 50mmhg facilitate the
	puncturing of the donor. Inflate cuff can be skipped by pressing the CONTINUE key
	☐ Enter the donor values like Sex, Height, weight and pre platelet and pre HCT count
	in the donor value entry screen and press OK key.

Very

Annexure – 4 Protocol for management of adverse reaction for Apheresis donations

Category Grade 1	Grade 2	Grade 3
A.1. Blood outside vessel Hematoma Arterial puncture Delayed bleeding Delayed bleeding	 OMC (EMR, ER, PCP, Urgent care), no hospitalization, or Activity of Daily Life (ADL) 2 weeks, or Generalized beyond venipuncture site 	 Hospitalization, or ADL ≤2 weeks, or Severe sequelae, or Surgical intervention
A.2. Arm pain Nerve injury /irritation Other arm pain	 OMC (EMR, ER, PCP, Urgent care), no hospitalization, or Duration>2 weeks to ≤6 months or (ADL) ≤2 weeks. 	Duration > 6 Months,ADL ≤2 weeks,
A.3.Localized Infection/inflammation of Vein or soft tissue Superficial thrombophlebitis Cellulitis	 OMC (EMR, ER, PCP, Urgent care), no hospitalization, or (ADL) ≤2 weeks, or Resolved with oral antibiotics 	 Hospitalization, or (ADL) < 2 weeks, or Resolved with IV treatment
A.4. Other major blood vessel injuryDeep venous thrombosis Arteriovenous fistula Compartment syndrome Brachial artery pseudoaneurysm		 Diagnoses medically confirmed, or Treated with anticoagulant therapy Required surgical intervention
B. Vasovagal reactionsVasovagal reaction, no loss of consciousness (LOC) Vasovagal reaction with LOC	 OMC (EMR, ER, PCP, Urgent care), no hospitalization, or (ADL) ≤2 weeks, or Suture of lacerations (s), or IV rehydration 	 Hospitalization, or (ADL) < 2 weeks, or Fracture (s), medically confirmed concussion, dental injury requiring dental procedure, e.g. cap/crown dental implant, bridge, tooth extractic dentures



The state of the s	• No OMC	• OMC (EMR, ER, PCP,	Hospitalization, or
	• Citrate toxicity	Urgent care), no	• (ADL) < 2 weeks, or
1	(including carpopedal	hospitalization, or	Abnormal cardiac rhythm
	spasm)	● (ADL) <u><</u> 2 weeks, or	medically diagnosed
Infiltration	Resolved with or	Citrate toxicity requiring	
r tone crem vision i	without oral calcium	intravenous calcium	
D. Allergic Reaction	• No OMC	• OMC (EMR, ER, PCP,	Hospitalization, or
Local allergic reaction	 Managed with over 	Urgent care), no	Generalized reaction
Generalized	- the counter	hospitalization, or	including bronchospasm,
(anaphylactic) reaction	medications :-	Generalized reaction	laryngospasmanaplhylaxis,
d'ora tudig	topical steroids,	including	requiring management
I a	antihistamine	bronchospasm,	with intravenous steroids
	al a cor eninepian ne put	laryngospasm managed	and / or epinephrine but
	To Tel To To America politica (19)	with inhalation or oral	NOT intubation or
		bronchodilator and / or	tracheostomy
	= 9	autoinjector (Epipen)	,
		automjector (Epiperi)	
E. Other serious			Diagnoses medically
complication			confirmed
Acute cardiacsymptom	ns	2	
Myocardial infarction	4		
Cardiac arrest			B
Transient ischemic	7 8	4	
attack		1	
Cerebrovascular		1 =	
accident (Stroke)		-	
accident (Stroke)			
		2	
F. Other	No OMC	OMC (EMR, ER, PCP,	Hospitalization, or
	 No injury 	Urgent care), no	 Duration >6 months,
			 ADL >2 weeks, or
	* · · · · · · · · · · · · · · · · · · ·	hospitalization, or	 Surgical intervention
		 Duration >2 weeks to 	
	a a	≤ 6 months or	
		● (ADL) <u><</u> 2 weeks	

(pail